Reduction in pro‐inflammatory cytokine profile and intestinal damage during in vivo experiments indicates that IL‐22 treatment may have restorative effects in the treatment of NEC by reducing excessive inflammation and enhancing epithelium healing. This evidence concerns the gene IL22 and necrotizing enterocolitis.